Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
Asenapine (Saphris - Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1331
Article Code: 1331a
Date: February 8, 2010
Volume: 52
Pages: 9-10
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1331
Article Code: 1331a
Date: February 8, 2010
Volume: 52
Pages: 9-10
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)